Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia

• Published in: Genome research
• Main Authors: Ferreira, Pedro G, Jares Gerboles, Pedro, Rico, Daniel, Gómez-López, Gonzalo, Martínez-Trillos, Alejandra, Villamor, Neus, Ecker, Simone, González-Pérez, Abel, Knowles, David G, Monlong, Jean, Johnson, Rory, Quesada, Victor, Djebali, Sarah, Papasaikas, Panagiotis, López-Guerra, Mónica, Colomer Pujol, Dolors, Royo, Cristina, Cazorla, Maite, Pinyol, Magda, Clot, Guillem, Aymerich Gregorio, Marta, Rozman, María, Kulis, Marta, Tamborero, David, Gouin, Anaïs, Blanc, Julie, Gut, Marta, Gut, Ivo, Puente, Xose S, Pisano, David G, Martín-Subero, José Ignacio, López-Bigas, Núria, López Guillermo, Armando, Valencia, Alfonso, López-Otín, Carlos, Campo Güerri, Elias, Guigó Serra, Roderic
• Format: Journal Article
• Language: English
• Published: Cold Spring Harbor Laboratory Press 21-11-2013
• Subjects: B cells; Chronic lymphocytic leukemia; Cèl·lules B; Expressió gènica; Gene expression; Genètica molecular; Leucèmia limfocítica crònica; Molecular genetics
• ISSN: 1088-9051

Chronic lymphocytic leukemia (CLL) has heterogeneous clinical and biological behavior. Whole-genome and -exome sequencing has contributed to the characterization of the mutational spectrum of the disease, but the underlying transcriptional profile is still poorly understood. We have performed deep RNA sequencing in different subpopulations of normal B-lymphocytes and CLL cells from a cohort of 98 patients, and characterized the CLL transcriptional landscape with unprecedented resolution. We detected thousands of transcriptional elements differentially expressed between the CLL and normal B cells, including protein-coding genes, noncoding RNAs, and pseudogenes. Transposable elements are globally derepressed in CLL cells. In addition, two thousand genes-most of which are not differentially expressed-exhibit CLL-specific splicing patterns. Genes involved in metabolic pathways showed higher expression in CLL, while genes related to spliceosome, proteasome, and ribosome were among the most down-regulated in CLL. Clustering of the CLL samples according to RNA-seq derived gene expression levels unveiled two robust molecular subgroups, C1 and C2. C1/C2 subgroups and the mutational status of the immunoglobulin heavy variable (IGHV) region were the only independent variables in predicting time to treatment in a multivariate analysis with main clinico-biological features. This subdivision was validated in an independent cohort of patients monitored through DNA microarrays. Further analysis shows that B-cell receptor (BCR) activation in the microenvironment of the lymph node may be at the origin of the C1/C2 differences.